OQS
IBRX icon

Occudo Quantitative Strategies’s ImmunityBio IBRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-399,046
Closed -$726K – 1140
2023
Q1 		$726K Buy
+399,046
New +$1.24M 0.07% 404
2022
Q1 		– Sell
-47,850
Closed -$291K – 1217
2021
Q4 		$291K Sell
47,850
-27,172
-36% -$204K 0.03% 780
2021
Q3 		$731K Buy
75,022
+55,323
+281% +$609K 0.09% 398
2021
Q2 		$281K Buy
+19,699
New +$325K 0.04% 623

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Occudo Quantitative Strategies's IBRX Position: Q2 2023 in Review

Occudo Quantitative Strategies sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 399,046 shares — an estimated $726K sold.

Occudo Quantitative Strategies first reported a position in IBRX in Q2 2021 and held it in 4 quarters. The position peaked at $731K in Q3 2021. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

  • Occudo Quantitative Strategies reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 399,046 ImmunityBio shares in Q2 2023, an estimated $726K.
  • Occudo Quantitative Strategies first reported a position in ImmunityBio in Q2 2021 and held it in 4 quarters.
  • Occudo Quantitative Strategies's ImmunityBio position peaked at $731K in Q3 2021.
  • 117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.